Skip to content

Trial · Observational

RecruitingPhase not statedRegistry data

Changes in Taste and Eating Habits Associated With GLP-1 Agonists in Weight Loss Patients

Short name GLP1-TASTE

NCTNCT07229170 (opens ClinicalTrials.gov in a new tab)Other idGLP1-TASTE
Open at ClinicalTrials.govAsk about this trial

This trial does not test a peptide that PepBank tracks.

  • Measures Semaglutide, does not give it. It appears in the eligibility rules.
  • Measures Tirzepatide, does not give it. It appears in the eligibility rules.

Overview

Status
Recruiting
Phase
Phase not stated
Enrollment
150 participants (estimated)
Sponsor
San Raffaele Telematic University · Other
Design
Not stated
Countries
1 country

Italy

Start
1 Dec 2025
Primary completion
1 Jan 2027 (estimated)
Completion
1 Jan 2028 (estimated)
First posted
14 Nov 2025
Last update posted
28 Apr 2026
Conditions
Obesity & Overweight · Taste Alterations · Weight Loss · Eating Behavior Changes

Timeline

1 trial · 1 ongoing

  • Completed
  • Ongoing
  • Not yet recruiting
  • Stopped
  • Estimated dates (est.)
  • Results posted
20252026202720282029
  1. Ph –

    GLP1-TASTE

    NCT07229170

    1 Dec 2025 to est. 1 Jan 2028

Registry summary

Text and fields below are the sponsor's entries at ClinicalTrials.gov, shown as posted.

This observational retrospective study aims to evaluate changes in taste perception, eating habits, and behavioral aspects in adults treated with GLP-1 receptor agonists for weight loss. Participants include adults aged 18-60 receiving treatment at specialized nutrition centers in Italy. Data are collected from clinical records, dietary questionnaires, and metabolic assessments before and after at least 12 weeks of GLP-1 agonist treatment. The study's primary goal is to understand how these treatments affect food preferences and taste perception. Secondary outcomes include changes in body weight, body composition, gastrointestinal side effects, and treatment adherence. All data are anonymized and collected according to ethical guidelines.

Arms1

  • Other

    GLP-1 Agonist Treated Patients

    This cohort includes adult patients aged 18-60 who have been treated with GLP-1 receptor agonists such as semaglutide or tirzepatide for weight loss in specialized nutrition centers in Italy. The study collects retrospective data on changes in taste perception, eating habits, body composition, and treatment adherence over a minimum duration of 12 weeks of therapy. No interventional treatments are administered as part of this observational study.

Primary outcomes1

Outcomes the sponsor listed as primary.

  1. Change in taste perception and food preferences

    Time frame · From baseline to 12 weeks after GLP-1 agonist treatment

    Registry description

    Assessment of patients' taste perception changes and shifts in eating habits using validated questionnaires and behavioral surveys.

Secondary outcomes(3)

  1. Change in body weight

    Time frame · From baseline to 12 weeks after treatment

    Registry description

    Measured in kilograms to assess weight loss effectiveness.

  2. Gastrointestinal side effects

    Time frame · Throughout the treatment period

    Registry description

    Recording of nausea, vomiting, diarrhea, or other GI symptoms via patient reports.

  3. Treatment adherence

    Time frame · Throughout the study duration

    Registry description

    Assessment of continued use and discontinuation reasons of GLP-1 agonists.

Posted results

Values are shown as posted at ClinicalTrials.gov, with their units. PepBank has not converted, pooled or compared them.

No results are posted for this trial.

A trial that is still running, or that stopped early, may post results later.

Registry data comes from ClinicalTrials.gov. Study results come from studies, not from the registry. How PepBank works

Studies1

Studies that cite this trial.

Studies with results

1 study on this page

Indexing hint: Randomized controlled trial · 2021

10 results

Once-Weekly Semaglutide in Adults with Overweight or Obesity.

Wilding et al. 2021The New England journal of medicinecited by 3,862

PMID 33567185DOI 10.1056/nejmoa2032183PUB-33567185

Full text at the publisher10 results
Publisher pageSee results (10)

Eligibility

Who could join, as posted.

Sex
All
Age
from 18 Years up to 60 Years
Healthy volunteers
Not accepted
Inclusion and exclusion criteria, as posted
Inclusion: Adults aged 18-60 years diagnosed with obesity and undergoing treatment with GLP-1 receptor agonists such as semaglutide or tirzepatide. Must have clinical records and dietary data available for at least 12 weeks of treatment. Exclusion: Patients with conditions affecting taste independent of GLP-1 treatment, severe comorbidities, or inability to provide consent and data.

PepBank is a research reference. Talk to a doctor before you use any peptide.